VA
ABCL icon

VestGen Advisors’s AbCellera Biologics ABCL Stock Holding History

VestGen Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Buy
19,652
+1,136
+6% +$5.55K ﹤0.01% 1047
2026
Q1 		$91.7K Buy
+18,516
New +$66.6K ﹤0.01% 1031

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

VestGen Advisors's ABCL Position: Q2 2026 in Review

VestGen Advisors increased its AbCellera Biologics (ABCL) stake by 6.1% in Q2 2026, buying an estimated $5.55K and bringing the position to 19,652 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #1047.

VestGen Advisors first reported a position in ABCL in Q1 2026 and has held it in 2 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • VestGen Advisors held 19,652 shares of AbCellera Biologics worth $154K as of Q2 2026.
  • VestGen Advisors bought 1,136 AbCellera Biologics shares in Q2 2026, an estimated $5.55K.
  • AbCellera Biologics made up ﹤0.01% of VestGen Advisors's portfolio in Q2 2026, its #1047 holding.
  • VestGen Advisors first reported a position in AbCellera Biologics in Q1 2026 and has held it in 2 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on VestGen Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.